Patricia Carr Sells 5,319 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 5,319 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $182.06, for a total value of $968,377.14. Following the completion of the sale, the chief accounting officer owned 7,012 shares of the company’s stock, valued at $1,276,604.72. This trade represents a 43.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Jazz Pharmaceuticals Stock Performance

JAZZ traded down $0.34 on Thursday, hitting $175.74. 1,664,525 shares of the company’s stock were exchanged, compared to its average volume of 947,213. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The stock has a fifty day moving average of $136.90 and a two-hundred day moving average of $121.57. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99. The firm has a market cap of $10.68 billion, a PE ratio of -26.11, a P/E/G ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. The business had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on JAZZ. Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research note on Monday. Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $195.07.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $25,000. Picton Mahoney Asset Management increased its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 234 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $36,000. Finally, Hantz Financial Services Inc. raised its holdings in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 297 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.